Anticoagulant News and Research RSS Feed - Anticoagulant News and Research

Anticoagulant fondaparinux lowers risk of major bleeding events, death in heart attack patients

Anticoagulant fondaparinux lowers risk of major bleeding events, death in heart attack patients

Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death both in the hospital and after six months compared to patients who received low-molecular-weight heparin (LMWH), although both groups had similar rates of subsequent heart attack or stroke, according to a study in the February 17 issue of JAMA. [More]
Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy. [More]
Surgical procedure for acute pulmonary embolism may actually prevent more deaths

Surgical procedure for acute pulmonary embolism may actually prevent more deaths

A surgical procedure that was virtually abandoned in the 1950s because of its high mortality rates in trying to save patients with acute pulmonary embolism may actually prevent more deaths in severely ill patients than current drug therapies alone, according to a new analysis of cases conducted in the North Shore-LIJ Health System over the past decade. [More]
Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. [More]
Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). [More]
Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at the 56th American Society of Hematology Annual Meeting and Exposition compare new and standard-of-care treatments for blood clots and further illuminate clot risks in vulnerable populations, such as cancer patients. [More]
Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)]. [More]
Having simultaneous chemotherapy and breast reconstruction after mastectomy may rise complications

Having simultaneous chemotherapy and breast reconstruction after mastectomy may rise complications

Immediate breast reconstruction following mastectomy is becoming more prevalent. However, in breast cancer patients undergoing simultaneous chemotherapy, thrombotic complications can arise that can delay or significantly modify reconstructive plans. Outcomes of cases illustrating potential complications are published in the current issue of Annals of Medicine and Surgery. [More]
Platelet-like nanoparticles mimic human body's coagulation process

Platelet-like nanoparticles mimic human body's coagulation process

Stanching the free flow of blood from an injury remains a holy grail of clinical medicine. Controlling blood flow is a primary concern and first line of defense for patients and medical staff in many situations, from traumatic injury to illness to surgery. [More]
FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF). [More]
University Medical Center's first atrial fibrillation unit opens in Germany

University Medical Center's first atrial fibrillation unit opens in Germany

Nearly 1.8 million people in Germany suffer from atrial fibrillation. This is the most common and clinically significant form of heart rhythm disorder. Shortness of breath, a sudden sense of dizziness, a feeling of pressure in the chest, and palpitations or thumping of the heart so extreme it can be felt beating rapidly and irregularly - this is how many patients describe their first episode of atrial fibrillation. [More]
UBC researchers set to develop universal antidote to simplify use of heparin

UBC researchers set to develop universal antidote to simplify use of heparin

Heparin, the life saving blood thinner used in major surgeries and treatment of heart diseases, is a complicated drug but a research team from the University of British Columbia has set out to make its use a lot safer by developing a universal antidote. [More]
Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%. [More]
Blood test can help identify people at increased risk of atrial fibrillation, stroke

Blood test can help identify people at increased risk of atrial fibrillation, stroke

Many of those who are genetically predisposed to develop atrial fibrillation, which dramatically raises the risk of stroke, can be identified with a blood test. This is shown by new research from Lund University in Sweden. [More]
New guidance can help physicians determine best oral blood thinners for patients

New guidance can help physicians determine best oral blood thinners for patients

Physicians around the world now have guidance that can help them determine the best oral blood thinners to use for their patients suffering from blood clots in their veins, thanks to a patient of The Ottawa Hospital who asked his physician a question he couldn't answer. [More]
Instrumentation Laboratory announces launch of HemosIL Direct Thrombin Inhibitor Assay in Europe

Instrumentation Laboratory announces launch of HemosIL Direct Thrombin Inhibitor Assay in Europe

Instrumentation Laboratory today announced the commercialization in Europe of their HemosIL Direct Thrombin Inhibitor (DTI) Assay. When used in conjunction with HemosIL Dabigatran Calibrators and Controls, this test offers an automated solution for the measurement of dabigatran, a direct oral anticoagulant (DOAC). [More]
Permanent atrial fibrillation twins risk of stroke than paroxysmal AF

Permanent atrial fibrillation twins risk of stroke than paroxysmal AF

Permanent atrial fibrillation (AF) doubles the risk of stroke compared to paroxysmal AF, according to research in more than 6 000 patients presented at ESC Congress today by Dr Thomas Vanassche from Belgium. The findings suggest that a simple clinical assessment of the type of AF can help doctors to better estimate stroke risk. [More]
Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Mortality and morbidity of atrial fibrillation (AF) patients remains high at one year despite good use of oral anticoagulants, according to the one year follow up of the Atrial Fibrillation General Pilot Registry. [More]
ESC launches first recommendations on use of all new oral anticoagulants in pulmonary embolism

ESC launches first recommendations on use of all new oral anticoagulants in pulmonary embolism

The first recommendations on the use of all new oral anticoagulants in pulmonary embolism are published today in new ESC Guidelines. [More]
Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations. [More]
Advertisement
Advertisement